mTOR Pathway Activation in Takayasu Arteriti

Cloé Comarmond¹, Aurélie Leroyer², Zeidan Mohamad³, Jean-Pierre Fourez⁴, Fabien Koskas⁵, Philippe Cluzel⁶, Anna Maciejewski-Duval⁷, Marlène Garrido⁸, Patrice Cacoub⁹ and David Saadoun¹⁰, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Hopital de Marseille, Marseille, France, ³Hopital Necker, Paris, France, ⁴Groupe Hospitalier Pitié-Salpétrière, Paris, France, ⁵Department of vascular surgery, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ⁶Department of cardiovascular imagery, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié Salpétrière, 83 Boulevard de l'Hôpital, 75013, Paris, France., Paris, France, ⁷GHPS, Paris, France, ⁸I3 laboratory, Pitié-Salpétrière, Paris, France, ⁹Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹⁰Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: mTor, takayasu arteritis and vasculitis

Session Information

Date: Monday, November 6, 2017

Title: T Cell Biology and Targets in Autoimmune Disease Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: mTORC1 drives the proinflammatory expansion of T helper (TH) type 1, TH17 cells and controls fibroblast proliferation, typical features of Takayasu arteritis (TA) pathogenesis. Molecular pathways involved in arterial lesions of TA are unknown.

Methods: We evaluate pathway activation in the mammalian target of rapamycin complex (mTORC) and the nature of cell proliferation in the vessels of patients with TA by using double immunostaining, western blot and flow cytometry.

Results: Proliferation of both endothelial cells and vascular smooth-muscle cells was shown in vascular lesions in TA. The vascular endothelium of proliferating aorta vessel from patients with TA showed indications of activation of the mTORC1 pathway. In cultured vascular endothelial cells, sera from patients with TA stimulated mTORC1 through the phosphatidylinositol 3-kinase (PI3K)–AKT pathway. Activation of mTORC was also found in Th1 and Th17 cells both systemically and in the blood vessels. Patients with TA exhibited a diminished AKT phosphorylation in Tregs. Inhibition of mTOR pathway with rapamycin increase Treg and decrease CD4+IFN+, CD4+IL17+ and CD4+IL21+ cells in patients with TA.

Conclusion: Our results suggest that the mTORC pathway is involved in the vascular lesions of Takayasu arteritis. Rapamycin could restore T cells homeostasis in patients with TA.

Disclosure: C. Comarmond, None; A. Leroyer, None; Z. Mohamad, None; J. P. Fourez, None; F. Koskas, None; P. Cluzel, None; A. Maciejewski-Duval, None; M. Garrido, None; P. Cacoub, None; D. Saadoun, None.

To cite this abstract in AMA style:

Comarmond C, Leroyer A, Mohamad Z, Fourez JP, Koskas F, Cluzel P, Maciejewski-Duval A, Garrido M, Cacoub P, Saadoun D. mTOR Pathway Activation in Takayasu Arteriti [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/mtor-pathway-activation-in-takayasu-arteriti/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mtor-pathway-activation-in-takayasu-arteriti/